// App-Quantinova.ai

: A Novel Risk-Model to Predict Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia Based on Heavy+Light Chain Immunoparesis and Serum Free Light Chain Analysis: Results from the Israeli CLL Study Group

Researchers

Presenter

  • Tamar Tadmor

Principal Investigators

  • Andrei Braester

  • Najib Dally

  • Ariel Aviv

  • Yair Herishanu

  • Mona Yuklea

  • Lev Shvidel

  • Naomi Rahimi-Levene

  • Rosa Ruchlemer

  • Ariela Arad

  • Claudia Fogl

  • Aaron Polliack

  • Lee Magal

  • Kelly Townsend

Medical Centers

  • Bnai Zion Medical Center The Ruth and Bruce Rappaport Faculty of Medicine,Technion, Haifa, Israel

  • Western Galilee Hospital, Nahariya, ISR

  • Faculty of Medicine, Bar Ilan University, Tel Aviv, Israel

  • Rheumatology, Emek Medical Center, Afula, Israel, Afula, Israel

  • Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

  • Department of Hematology, Meir Medical Center, Kfar Saba, Israel, KFAR SAVA, ISR

  • Kaplan Medical Center, Rehovot, Israel

  • Assaf Harofeh Medical Center, Zerifin, Israel

  • Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel

  • Laniado Hospital, Netanya, Israel

  • The Binding Site Group Ltd, The Binding Site Group Ltd, United Kingdom

  • Hadassah Medical Organization, Eln Karem, Jerusalem, ISR

  • The Binding Site, Tel Aviv, Israel

  • The Binding Site Group Ltd, Head Of Medical Science Liaison-Monoclonal Gammopathy, Birmingham, United Kingdom

Locations

  • Israel

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • Immunoglobulin G

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved